Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Medivir announces first patient enrolled in FLEX-HCC study
Regulatory Filings Classification · 65% confidence The document is a corporate press release announcing clinical trial enrollment (FLEX-HCC study), with no financial results, management changes, governance details, or investor presentation materials. It does not fit any specific category such as earnings release, capital update, M&A, or interim report. It is a general regulatory announcement required under EU Market Abuse Regulation, so it falls under the fallback category for miscellaneous regulatory filings.
2026-05-21 English
Medivir meddelar att första patienten har inkluderats i FLEX-HCC-studien
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing the inclusion of the first patient in a Phase 2 clinical trial. It contains no financial statements, no earnings or management changes, and is not presenting any formal report. It is a mandatory disclosure under EU Market Abuse Regulation, fitting the “Regulatory Filings” fallback category for miscellaneous announcements. Therefore, it should be classified as RNS.
2026-05-21 Swedish
Resolutions at the Annual General Meeting in Medivir on 7 May 2026
AGM Information Classification · 100% confidence The document is a press release dated 7 May 2026, detailing the resolutions passed at Medivir's Annual General Meeting (AGM). It includes approval of financial statements, discharge of board members, election of board members and auditors, remuneration decisions, authorization to issue new shares, and adoption of a share price-related remuneration program for the board. The content is typical of AGM resolutions and materials shared during the AGM, focusing on governance and shareholder decisions. There is no detailed financial report or earnings data, nor is it a notice of voting results only. The document is not a report publication announcement but the actual AGM resolutions. Therefore, the appropriate classification is AGM Information (AGM-R).
2026-05-07 English
Beslut vid årsstämma i Medivir den 7 maj 2026
AGM Information Classification · 95% confidence The document is a press release dated May 7, 2026, reporting on the decisions made at Medivir's Annual General Meeting (AGM) held on the same day. It details resolutions such as approval of financial statements, discharge of board members, election of board members and auditors, approval of remuneration reports, authorization for share issuance, and adoption of an incentive program for the board. The content is focused on the outcomes and decisions of the AGM rather than the full annual report or financial statements themselves. The document length is about 4,828 characters, which is relatively short and consistent with an announcement of AGM decisions rather than a full report. Therefore, the document fits the category of AGM Information (AGM-R).
2026-05-07 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Delårsrapport januari – mars 2026' which translates to 'Interim Report January – March 2026'. It contains detailed financial data for the quarter, including revenue, EBITDA, cash flow, and cash position. It also discusses significant events during the quarter such as changes in the board, a directed share issue, clinical study updates, and management appointments. The document includes management commentary ('Vd har ordet'), detailed project pipeline updates, clinical trial phases, and financial summaries. The length is substantial (15,000 characters) and contains substantive financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). It is not an announcement of a report, nor a certification or a brief summary. Therefore, the correct classification is IR with high confidence. Q1 2026
2026-05-05 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Medivir AB – Interim Report January – March 2026' and contains detailed financial data for the quarter, including net turnover, EBITDA, earnings per share, cash flow, and cash position. It also discusses significant events during the quarter such as board changes, share issues, clinical study updates, and management appointments. The document includes a CEO's message, detailed descriptions of proprietary projects, clinical study phases, and results. The content is comprehensive and covers a period shorter than a full fiscal year (a quarter). It contains substantive financial data and analysis, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-05 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.